These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Well differentiated follicular thyroid neoplasia: impact of molecular and technological advances on detection, monitoring and treatment. Gianoukakis AG; Giannelli SM; Salameh WA; McPhaul LW Mol Cell Endocrinol; 2011 Jan; 332(1-2):9-20. PubMed ID: 21094678 [TBL] [Abstract][Full Text] [Related]
3. Detection of RAS mutation by pyrosequencing in thyroid cytology samples. Guerra A; Carrano M; Angrisani E; Puzziello A; Izzo G; Di Crescenzo V; Vatrella A; Vitale M Int J Surg; 2014; 12 Suppl 1():S91-4. PubMed ID: 24866065 [TBL] [Abstract][Full Text] [Related]
4. ROLE OF MOLECULAR MARKERS IN THYROID NODULE MANAGEMENT: THEN AND NOW. Nikiforov YE Endocr Pract; 2017 Aug; 23(8):979-988. PubMed ID: 28534687 [TBL] [Abstract][Full Text] [Related]
6. Predicting malignancy in thyroid nodules: molecular advances. Melck AL; Yip L Head Neck; 2012 Sep; 34(9):1355-61. PubMed ID: 21818817 [TBL] [Abstract][Full Text] [Related]
7. Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis. Vuong HG; Altibi AM; Duong UN; Ngo HT; Pham TQ; Tran HM; Oishi N; Mochizuki K; Nakazawa T; Hassell L; Katoh R; Kondo T Tumour Biol; 2017 Oct; 39(10):1010428317713913. PubMed ID: 29037127 [TBL] [Abstract][Full Text] [Related]
8. Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics. Radkay LA; Chiosea SI; Seethala RR; Hodak SP; LeBeau SO; Yip L; McCoy KL; Carty SE; Schoedel KE; Nikiforova MN; Nikiforov YE; Ohori NP Cancer Cytopathol; 2014 Dec; 122(12):873-82. PubMed ID: 25132659 [TBL] [Abstract][Full Text] [Related]
9. Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules. Beaudenon-Huibregtse S; Alexander EK; Guttler RB; Hershman JM; Babu V; Blevins TC; Moore P; Andruss B; Labourier E Thyroid; 2014 Oct; 24(10):1479-87. PubMed ID: 24811481 [TBL] [Abstract][Full Text] [Related]
10. Genetic Alterations in Hungarian Patients with Papillary Thyroid Cancer. Tobiás B; Halászlaki C; Balla B; Kósa JP; Árvai K; Horváth P; Takács I; Nagy Z; Horváth E; Horányi J; Járay B; Székely E; Székely T; Győri G; Putz Z; Dank M; Valkusz Z; Vasas B; Iványi B; Lakatos P Pathol Oncol Res; 2016 Jan; 22(1):27-33. PubMed ID: 26259532 [TBL] [Abstract][Full Text] [Related]
11. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma. An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485 [TBL] [Abstract][Full Text] [Related]
12. DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival. Mancikova V; Buj R; Castelblanco E; Inglada-Pérez L; Diez A; de Cubas AA; Curras-Freixes M; Maravall FX; Mauricio D; Matias-Guiu X; Puig-Domingo M; Capel I; Bella MR; Lerma E; Castella E; Reverter JL; Peinado MÁ; Jorda M; Robledo M Int J Cancer; 2014 Aug; 135(3):598-610. PubMed ID: 24382797 [TBL] [Abstract][Full Text] [Related]
13. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland. Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135 [TBL] [Abstract][Full Text] [Related]
15. RAS Mutations, and RET/PTC and PAX8/PPAR-gamma Chromosomal Rearrangements Are Also Prevalent in Benign Thyroid Lesions: Implications Thereof and A Systematic Review. Najafian A; Noureldine S; Azar F; Atallah C; Trinh G; Schneider EB; Tufano RP; Zeiger MA Thyroid; 2017 Jan; 27(1):39-48. PubMed ID: 27750019 [TBL] [Abstract][Full Text] [Related]
16. Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis. Park SJ; Sun JY; Hong K; Kwak JY; Kim EK; Chung WY; Choi JR Clin Chem Lab Med; 2013 Aug; 51(8):1673-80. PubMed ID: 23585181 [TBL] [Abstract][Full Text] [Related]
17. Prognostic value of genetic mutations in thyroid cancer: a meta-analysis. Pak K; Suh S; Kim SJ; Kim IJ Thyroid; 2015 Jan; 25(1):63-70. PubMed ID: 25244593 [TBL] [Abstract][Full Text] [Related]
18. [The advances of molecular pathology of follicular thyroid carcinoma]. Zhan Y; Cui QC Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):268-70. PubMed ID: 15256127 [No Abstract] [Full Text] [Related]
19. Genetic-guided Risk Assessment and Management of Thyroid Cancer. Xing M Endocrinol Metab Clin North Am; 2019 Mar; 48(1):109-124. PubMed ID: 30717896 [TBL] [Abstract][Full Text] [Related]
20. Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors. Jung CK; Kim Y; Jeon S; Jo K; Lee S; Bae JS Hum Pathol; 2018 Nov; 81():9-17. PubMed ID: 29723601 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]